Cartesian Therapeutics Q3 net loss narrows

Overview

• US cell therapy developer's Q3 net loss narrows from prior year

• Company's operating expenses rose on higher R&D spending for Phase 3 AURORA trial

• Cash position of $124.7 mln expected to fund operations into 2028

Outlook

• Company expects Phase 3 AURORA trial data readout in 1Q27 and BLA filing mid-2027

• Data from TRITON and HELIOS trials expected in 1H27

• Company expects current cash resources to support planned operations into 2028

Result Drivers

• CLINICAL TRIAL SPENDING - Higher R&D expenses driven by Phase 3 AURORA trial and Phase 2 TRITON trial for Descartes-08

• COMMERCIAL PREPARATION - Expansion of medical affairs and commercial teams to support launch readiness for Descartes-08

• ADMINISTRATIVE COSTS - Rise in general and administrative expenses due to higher professional fees and employee-related costs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cartesian Therapeutics, Inc. is $38.50, about 464.5% above its November 4 closing price of $6.82

Reuters Recommended Reads

• Nov 4 - Lyell Immunopharma Q3 net loss widens on higher R&D spending

• Nov 4 - Summit Therapeutics reports Q3 loss on higher R&D spending

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)